Objectives: It is questionable whether the stress response to surgery is necessary. The objective of this study was to evaluate the effectiveness of postoperative analgesia on energy metabolism and compare cyclooxygenase-2 selective inhibitor with tramadol in postoperative pain management after major abdominal surgery.
T he insult of operative trauma can be considered as a particular form of injury. The overall metabolic effect of stress response to surgery is mobilizing substrates from carbohydrate, lipid, and protein stores to provide energy sources. 1, 2 It seems likely that the stress response to trauma develops as a survival mechanism in evolutionary terms. However, it is questionable whether the stress response is necessary. A constant high level of stress can cause physical problems as the body does not have an opportunity to return to normal. Studies [3] [4] [5] showed that most critically ill patients have evidence of an increased metabolic response and catabolism of body stores, whereas hypermetabolism is associated with complications such as hyperglycemia, hypoproteinemia, and immunosuppression. 6, 7 Therefore, an attempt to reduce or even prevent some of the surgical stress response is needed. However, routine postoperative pain management or studies (usually within 72 h after surgery) showed unsatisfactory of pain relief. About 30% to 80% of patients report moderate to severe pain after surgery, especially for patients after abdominal surgery. 8, 9 Inadequate pain relief may increase responses to operative stress, delay recovery, and increase hospital stay. 10 Although various studies in the fields of surgery and anesthesia target reduction surgical stress response, few studies focus on the benefit of pain relief on metabolism in adults after abdominal surgery.
Tramadol is a centrally acting analgesic agent that is very similar in structure to morphine and codeine. However, tramadol had no clinically relevant effects on cardiovascular and respiratory parameters and little clinically relevant effects on gastrointestinal function in comparison with other opioids. 11, 12 Thus, parenteral or oral tramadol is commonly used after abdominal surgery. Currently, cyclooxygenase (COX)-2 selective inhibitor drugs like parecoxib are thought to have beneficial effects on inflammation and reduction in the incidence of side effects after noncardiac surgery. 13, 14 However, previous work, such as Malan et al 15 and Grundmann et al, 16 deal mainly with efficacy of parecoxib, morphine, or other nonsteroidal antiinflammatory drugs (NSAIDs) after nonabdominal surgery. Studies on effectiveness of COX-2 inhibitor and comparison of parecoxib and tramadol for postoperative pain relief after major abdominal surgery have been less discussed. The purpose of this paper is to present the design of a randomized controlled, double-blind trial to evaluate the effectiveness of postoperative analgesia on energy metabolism and role of COX-2 inhibitors in postoperative pain management after major abdominal surgery in adults.
METHODS

Participant Selection
This study was approved by the Ethics Committee of the Medical Faculty of Jinling Hospital. The procedures followed were in accordance with the Helsinki Declaration of 1975, as revised in 1989.
A total of 160 successive patients scheduled for elective major abdominal surgery were considered for participation in the study from mid 2011 to early 2012. Inclusion criteria were age 18 to 70 years and ASA physical status I to II. Patients with a history of alcohol, analgesic, or narcotic abuse; using analgesics, neuroleptics, antipsychotic agents, or corticosteroids within 6 hours of surgery; allergy to conventional NSAIDs; significant cardiac, pulmonary, hepatic, or renal disease were excluded. Females with a positive pregnancy test and patients unable to cooperate were excluded. If the patient met all the inclusion and none of the exclusion criteria, they were invited to the clinic for a detailed explanation of the study and requirements of informed consent. A total of 112 patients were included and finally 99 patients completed it. A flowchart of the patient screening, enrollment, randomization, and analysis is shown in Figure 1 .
After written informed consent, patients were randomly assigned to one of the 4 treatment groups before abdominal surgery. Randomization was performed using a sealed opaque envelope with computer-generated random allocation block. The 4 study groups were (1) parecoxib/ control; (2) parecoxib/celecoxib; (3) tramadol/control; and (4) tramadol/tramadol.
Anesthetic Procedure
All patients had fasted overnight, and a standard anesthetic regimen was used. On the day of surgery, patients were premedicated with 0.1 g of phenobarbital and 0.3 mg of scopolamine intramuscularly half an hour before anesthesia. On arrival in the operation room, an 18-G cannula was inserted into a forearm vein and standard monitors were applied. A Swan-Ganz catheter and the radial artery catheter were placed to monitor mean arterial pressure, heart rate, central venous pressure, mean pulmonary arterial pressure, and noninvasive arterial blood pressure was recorded every 5 minutes throughout anesthesia. Ringer's lactate was intravenously infused at a rate of 5 mL/kg/h over 20 minutes. General anesthesia was induced in all patients with 0.05 mg/kg midazolam, 2 mg/kg propofol, and 3.0 mg/kg fentanyl followed by 0.6 mg/kg rocuronium (Organon, Holland) to facilitate tracheal intubation and to maintain neuromuscular blockade, and neuromuscular blockade was achieved with continuous infusion of vecuronium (0.06 mg/kg/h). Tracheas were intubated and patients' lungs mechanically ventilated with a tidal volume (VT) of 10 to 12 mL/kg and a respiratory rate of 12 breaths/ min. Maintenance of anesthesia was achieved with isoflurane (MAC 0.8 to 1.2) and continuous intravenous infusion of fentanyl (1.0 to 2.0 mg/kg/h). After surgery, patients were transferred to the postanesthesia care unit, where the tracheal tube was removed after the patient had regained consciousness and was able to maintain adequate ventilation and follow commands. Thereafter, the patients were directly transferred to surgical intensive care unit for further treatment and clinical observations, which were done by an independent, blinded observer who was unaware of the administered study drugs. Most patients were transferred to the general wards 2 or 3 days later.
Analgesic Drug Delivery and Protocol Design
At the end of surgery, all patients were treated for pain immediately by using morphine (20 mg) and tramadol (0.3 g) delivered by standard patient-controlled analgesia, which was continued until the morning after surgery. Thereafter, patients were scheduled to receive different analgesic drugs according to randomization for 1-week period of treatment:
Group parecoxib/control: intravenous parecoxib (IV 40 mg bid) from the first morning after surgery to day 3 after surgery and placebo from day 4 to 1 week after surgery.
Group parecoxib/celecoxib: intravenous parecoxib (IV 40 mg bid) from the first morning after surgery to day 3 after surgery and oral celecoxib (PO 0.2 mg bid) day 4 to 1 week after surgery.
Group tramadol/control: intravenous tramadol (IV 0.1 g tid) from the first morning after surgery to day 3 after surgery and placebo from day 4 to 1 week after surgery.
Group tramadol/tramadol: intravenous tramadol (IV 0.1 g tid) from the first morning after surgery to day 3 after surgery and oral tramadol (PO 0.1 g tid) from day 4 to 1 week after surgery.
The rationale for choosing the dosage we used was based upon instructions of manufacturer and medication guideline. In the postsurgical period, rescue medication was allowed at any time when the patient requires and was administered in according with the standard practices at our hospital policy. If rescue medication (morphine 0.1 mg/kg intramuscular) was administered, time to rescue (time between administration of study drug and administration of rescue medication) was recorded. In addition, patients who took rescue medication completed no additional pain measurements and record of experiments during the study period.
Efficacy Assessments
The primary end point of the study was measured resting energy expenditure (REE). Secondary end points were pain assessment (at rest and during leg raising) and adverse events. At baseline, study measures (ie, medical history, physical examination, vital signs, pain intensity assessments, and any adverse events related to analgesic therapies) were obtained in all participating patients 1 or 2 days before surgery. These study measures will be repeated every day postoperatively.
REE was used in this study to evaluate the caloric and substrate needs of our patients. REE represents the demand for energy (kcal/d) to support life and can be determined using indirect calorimetry that measures oxygen consumed and carbon dioxide produced. 17 REE was measured in the morning after an overnight fast under resting conditions at baseline and follow-up using the method described in our previous study. 18 The measurement was carried out for 20 minutes, with the patient in the supine position under standard conditions of rest, fasting, immobility, thermoneutrality (22 to 241C), and mental relaxation. Then, REE was normalized by kg of body weight resulting in energy expenditure in kcal/kg/d. REE was obtained at baseline and will be repeated at day 3 and 1 week after surgery under the same conditions.
Pain intensity at rest and during leg raising was recorded daily at 4 different times (08:00 AM, 10:00 AM, 2:00 PM and 4:00 PM) in a quiet environment (baseline assessment taken before surgery), unless rescue medication was requested. The daily pain score was the mean of the pain intensity at the 4 different times of that day. Pain intensity was evaluated by numeric rating scale (NRS) or faces rating scale (FRS). The NRS is a frequently used method of subjectively scoring pain: on a horizontal line with a scale from 0 to 10, with 0 representing no pain and 10 representing worst possible pain. Patients are asked to choose a number that relates to their current pain intensity. Adults who have difficulty using NRS were assisted with FRS. The FRS is another frequently used method, especially for older patients. There are 6 facial expressions suggesting various pain intensities. The far left face with a slight smile indicates "no hurt" and the far right face with great sadness indicates "hurts worst." Instruct the patient to choose the face that best describes the pain they feel. The face that depicts "no hurt" would be scored 0 points. The remaining faces are scored from 2 to 10 points depending upon the severity of the pain depicted by the face. The numeric notation for the faces on the scale is not displayed to the patient.
Clinical tolerability and occurrence of adverse events were registered throughout the treatment period. In general, adverse events include nausea, vomiting, headache, urinary retention, somnolence, flatulence, and pruritus. We used G*Power 3.1 19 for power calculation. Calculation of sample size was based on the primary end point (REE) and our primary experimental results. Given means of REE and SD with an a-level of 2-sided type I error (0.05, Bonferroni corrected for 2 comparisons) and with a b-level of type II error (0.20; ie, 80% power), a minimum of 20 patients per group or a total of 80 participants for the trial was required. The inclusion of at least 90 patients was advised to accommodate for a 10% drop out.
For statistical analyses, SPSS 16.0 was used. A 2-tailed probability value of <0.05 was used as a criterion for statistical significance. Descriptive data were presented as number with percentage, mean with SD, as appropriate. w 2 test for qualitative data and 1-way ANOVA for quantitative data were applied to detect differences between groups at baseline. Differences between baseline and follow-up were assessed using a paired t test. To detect differences in the end points between groups were determined by a 1-way ANOVA, followed by the Student-Newman-Keuls test. A probability value of P < 0.05 is considered significant.
RESULTS
A total of 112 patients were enrolled in the study from mid 2011 until early 2012; 28 patients were randomized to each of the 4 treatment groups. Of the 112 eligible patients, 99 (88.4%) patients gave informed consent and completed this study. No statistically significant differences in baseline demographics were found (Table 1) . A total of 13 (11.6%) patients were withdrawn from the study: 3 in the parecoxib/ control group, 4 in the parecoxib/celecoxib group, 4 in the tramadol/control group, and 2 in the tramadol/tramadol group. The reasons for withdrawal were rescue medication, receiving interfering drug, refusing to participate, and surgical complications.
REE
The measured REE for each group at each time point are shown in Figure 2 . There were no significant differences in REE between the groups on day 3 after surgery. However, patients in group tramadol/tramadol showed much lower mean REE compared with group tramadol/control 1 week after surgery (P < 0.05, Fig. 2A ). The measured REE was significantly lower in patients treated with analgesic drugs on day 4 to 7 after surgery relative to placebo patients (P < 0.01, Fig. 2B ).
Pain Intensity
Pain intensity ratings at rest and during leg raising decreased significantly within 3 days after surgery for each group (P < 0.05, Fig. 3 ). There was no statistically significant difference in pain intensity ratings between groups during the first 3 days after surgery. From the fourth day after surgery, groups parecoxib/celecoxib and tramadol/ tramadol showed significantly lower pain intensity ratings by ANOVA compared with groups parecoxib/control and tramadol/control during leg raising(P < 0.05 Fig. 3B ). No significant differences were found at any time when comparing group parecoxib/celecoxib with group tramadol/tramadol and group parecoxib/control with tramadol/control.
The Incidence of Adverse Events
There were no signs of allergy during our study. The incidence of adverse events (AEs) reported by at least 5% of patients in any treatment group is summarized in Table 2 . The most frequently reported AE were nausea, vomiting, flatulence urinary retention, and fever. No significant differences were shown between 4 treatment groups. Most incidences of AE were typical of the postoperative setting. Overall, 18 (64.3%) patients in the parecoxib/control group, 20 (71.4%) patients in the parecoxib/celecoxib group, 14 (50.0%) patients in the tramadol/control group, and 17 (60.7%) patients in the tramadol/tramadol group had AE during our study.
DISCUSSION
This is the first prospective, randomized controlled, double-blind trial to evaluate the effectiveness of postoperative analgesia on energy metabolism and compare COX-2 inhibitors with tramadol in postoperative pain management after major abdominal surgery. The main results of our study demonstrate that sufficient and effective analgesia for up to 7 days after surgery can reduce the elevated level of REE.
Surgical trauma trigger a series of complex metabolic host responses designed to maintain homeostasis and ensure survival. 20 The overall metabolic effect is increased catabolism that mobilizes substrates from carbohydrate, lipid, and protein stores to provide energy sources. In the 1930s, Cuthbertson first introduced the short-term metabolic rate decreased immediately after injury and surgery, followed by a period characterized by an increase in REE, which may take several days, and then documented about 20% to 25% of the increased metabolic rate. 1, 21, 22 Moreover, this hypercatabolic condition may results in significantly increase in oxygen consumption and energy consumption-a state associated with severe complications related to hyperglycemia, hypoproteinemia, and immunosuppression. 6, 7 Therefore, there is a place for trying to reduce some of the responses to postoperative stress including hypermetabolism.
Failure in pain relief may affect energy metabolism in a couple of ways. Inadequate postoperative pain relief can increase responses to operative stress and decrease early ambulation, 10 which is undesirable because the long-term stay in bed may increases muscle loss and weakness, impairs pulmonary function, and tissue oxygenation. 23 In addition, surgical procedures, especially of the chest and upper abdomen, lead to important changes in respiratory function, 24 which may further increase tissue oxygenation and delay recovery. Therefore, sufficient pain relief is a prerequisite for attempting to reduce operative stress and maintain normal energy metabolism after surgery. Our results demonstrated that sufficient pain relief after surgery could truly reduced the elevated level of REE, although persistent elevations of REE could still be found as long as 1 week after surgery. The persistent elevation in REE in our study was consistent with previous studies that showed sustained high metabolism of at least 7 days, and in many severely injured patients, up to 3 weeks. 25, 26 Besides, early postoperative mobilization could also be a factor in persistent elevation of REE in our study. Opioid analgesics and NSAIDs are useful agents for treatment of various pain problems. However, the potential AE such as respiratory depression, gastrointestinal reactions, and perioperative bleeding complications limit their use in abdominal surgery. 27, 28 A new class of NSAIDs, such as parecoxib, COX-2-specific inhibitor, seems to have a role in the postoperative pain management. These drugs inhibit COX-2, which is responsible for inflammation and pain, and have little or no effect on COX-1, which is responsible for the maintenance of gastrointestinal mucosal integrity and platelet function. Most of the previous placebo-controlled studies had shown that the use of parecoxib could improve pain control, reduce opioid consumption, and reduce postoperative side effects. 15, 16, [29] [30] [31] However, studies on effectiveness of COX-2 inhibitor after major open abdominal surgery is less discussed. Currently, parenteral or oral tramadol is commonly used because of its powerful analgesic effect and less relevant effects on gastrointestinal function. 11 Our study indicated that intravenous parecoxib (IV 40 mg bid.) for 3 days with continued oral celecoxib (PO 0.2 g bid) was as efficient as intravenous tramadol (IV 0.1 g tid) for 3 days with continued oral tramadol (PO 0.1 g tid) after major open abdominal surgery. In addition, there was no significant difference in the incidence of adverse events in our study, whereas most incidences of AE were typical of the postoperative setting.
The study also has certain limitations. It has been suggested that multimodal or balanced analgesia that use a combination of opioid analgesics, local anesthetics, or nerve blocks is a rational approach to pain management and is more effective. 32, 33 However, previous guidelines for optimizing multimodal perioperative pain management did not consider procedure-specific issues, and the regimens of multimodal analgesia vary according to different types of surgical procedures. 34 Even though it is unsuitable to use Numeric rating scale or faces rating scale were used. wP < 0.05, value compared with the first day after surgery in each group using a paired t test; *P < 0.05, significance between treatment and placebo groups at time points indicated according to the ANOVA test with post hoc tests by Student-Newman-Keuls. FIGURE 2. The measured resting energy expenditure (REE) for each group (A) and for treatment and placebo groups (B) at each time point. *P < 0.05, the P value is from the Student-NewmanKeuls test following significant ANOVA; **P < 0.01. multimodal analgesia in our study, studies focused on the effect of postoperative multimodal analgesia on energy metabolism should also be conducted in the future. In addition to this, the long-term monitoring fluctuation of energy metabolism is needed. Whether oxygen consumption and metabolic rate responses to major abdominal surgery are altered by long-term postoperative analgesia is not known. Therefore, an ongoing randomized, controlled, double-blind, large-scale, and long-term clinical investigation evaluating the effectiveness and safety of postoperative analgesia on energy metabolism is imperative. It should also be noted that whether combination of COX-2 inhibitor with other analgesic drugs after gastrointestinal surgery could achieve a reduction of opioid-related side effects, and further largescale research into both the early prognosis and the daily life of recovery (eg, mobilization, recovery of bowel function, and return to work) are required.
In summary, this trial may be the first time to report the effectiveness of postoperative analgesia on energy metabolism after major abdominal surgery. This study may give evidence for clinicians to reduce, and even prevent, some of the responses to operative stress with sufficient postoperative analgesia. In addition, intravenous parecoxib (IV 40 mg bid) followed by oral celecoxib (PO 0.2 g bid) is as effective as intravenous tramadol (IV 0.1 g tid) with continued oral tramadol (PO 0.1 g tid). Considering the potential little gastrointestinal adverse effects of tramadol and the beneficial effects on inflammation of COX-2 selective inhibitor, parecoxib followed by oral cerecoxib seems to be an attractive option after abdominal surgery. Data are given as number (%).
No difference between groups.
